Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells Jul 7, 2023 | Uncategorized
Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC) Jul 7, 2023 | Prostate
Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2+ pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice Jul 7, 2023 | Uncategorized
Phase I Trial Characterizing the Pharmacokinetic Profile of N-803, a Chimeric IL-15 Superagonist, in Healthy Volunteers Jul 7, 2023 | Uncategorized
Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy Jun 29, 2023 | Articles, Breast Cancer
